Help Ensure Access to Paxlovid for COVID-19

July 2022

You play a key role in limiting treatment delays with Paxlovid (nirmatrelvir/ritonavir) for patients with COVID-19.

Help HIGH-risk patients start within the 5-day window.

Dispensing. Any type of positive COVID-19 test is enough to qualify for Paxlovid, even a home test. And the med is still no cost to patients.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote